We are live on ! Find out more
ECOR icon

electroCore

8.98 USD
-0.23
2.5%
At close Updated Sep 8, 12:37 PM EDT
1 day
-2.5%
5 days
-3.65%
1 month
0.22%
3 months
-6.85%
6 months
35.24%
Year to date
97.36%
1 year
82.52%
5 years
-40.09%
10 years
-96.98%
 

About: electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.

Employees: 83

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 9.1%
Neutral 81.8%
Negative 9.1%
Neutral
GlobeNewsWire
14 days ago
electroCore's Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards
Recognition highlights Truvaga's combination of patented non-invasive vagus nerve stimulation technology, thoughtful design and personalized wellness experience Recognition highlights Truvaga's combination of patented non-invasive vagus nerve stimulation technology, thoughtful design and personalized wellness experience
electroCore's Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards
Neutral
Seeking Alpha
1 month ago
electroCore, Inc. (ECOR) Q2 2026 Earnings Call Transcript
electroCore, Inc. (ECOR) Q2 2026 Earnings Call Transcript
electroCore, Inc. (ECOR) Q2 2026 Earnings Call Transcript
Positive
MarketBeat
1 month ago
electroCore Q2 Earnings Call Highlights
electroCore NASDAQ: ECOR reported second-quarter 2026 revenue of $9.5 million, up approximately 28% from $7.4 million a year earlier, as growth in Veterans Affairs prescription sales and direct-to-consumer Truvaga sales lifted results. The company raised its full-year revenue outlook to growth of more than 30% over 2025 and said it is targeting positive adjusted EBITDA in the third quarter of 2027.
electroCore Q2 Earnings Call Highlights
Negative
Zacks Investment Research
1 month ago
electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates
electroCore, Inc. (ECOR) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.35 per share a year ago.
electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
electroCore Announces Second Quarter 2026 Financial Results
Second quarter 2026 net sales of $9.5 million, an increase of 28% over $7.4 million in the second quarter 2025 Net loss of $3.1 million decreased 17% from prior year with Adjusted EBITDA net loss improving 26% from prior-year period Increasing 2026 revenue guidance to greater than 30% year-over-year growth Company to host a conference call and webcast today, August 6, 2026, at 4:30 pm EDT ROCKAWAY, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced financial results for the second quarter ended June 30, 2026.
electroCore Announces Second Quarter 2026 Financial Results
Neutral
GlobeNewsWire
1 month ago
electroCore to Participate in Upcoming Investor Conferences
ROCKAWAY, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following investor conferences:
electroCore to Participate in Upcoming Investor Conferences
Neutral
GlobeNewsWire
1 month ago
electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026
ROCKAWAY, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the second quarter ended June 30, 2026, after the close of the market on Thursday, August 6, 2026.
electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026
Neutral
GlobeNewsWire
1 month ago
New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation
ROCKAWAY, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced the publication of the peer-reviewed review article, "Two Paths to the Body's Superhighway—The Auricular Branch (taVNS) and the Cervical Bundle (tcVNS): A Narrative Review," in Frontiers in Neuroscience. The article was authored by Peter S. Staats, MD, MBA, Chief Medical Officer of electroCore, and Justyna Blake, Senior Director of Medical Affairs at electroCore.
New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation
Neutral
Seeking Alpha
2 months ago
electroCore, Inc. (ECOR) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript
electroCore, Inc. (ECOR) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript
electroCore, Inc. (ECOR) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript
Neutral
GlobeNewsWire
2 months ago
electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference
ROCKAWAY, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will participate in the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23-24, 2026.
electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference
Price charts implemented using Lightweight Charts™